Zhang Zheng, Cheng Liang, Zhao Juanjuan, Li Guangming, Zhang Liguo, Chen Weiwei, Nie Weiming, Reszka-Blanco Natalia J, Wang Fu-Sheng, Su Lishan
J Clin Invest. 2015 Sep;125(9):3692-703. doi: 10.1172/JCI82124. Epub 2015 Aug 24.
Group 3 innate lymphoid cells (ILC3s) have demonstrated roles in promoting antibacterial immunity, maintaining epithelial barrier function, and supporting tissue repair. ILC3 alterations are associated with chronic inflammation and inflammatory disease; however, the characteristics and relevant regulatory mechanisms of this cell population in HIV-1 infection are poorly understood due in part to a lack of a robust model. Here, we determined that functional human ILC3s develop in lymphoid organs of humanized mice and that persistent HIV-1 infection in this model depletes ILC3s, as observed in chronic HIV-1-infected patients. In HIV-1-infected mice, effective antiretroviral therapy reversed the loss of ILC3s. HIV-1-dependent reduction of ILC3s required plasmacytoid dendritic cells (pDCs), IFN-I, and the CD95/FasL pathway, as targeted depletion or blockade of these prevented HIV-1-induced ILC3 depletion in vivo and in vitro, respectively. Finally, we determined that HIV-1 infection induces CD95 expression on ILC3s via a pDC- and IFN-I-dependent mechanism that sensitizes ILC3s to undergo CD95/FasL-mediated apoptosis. We conclude that chronic HIV-1 infection depletes ILC3s through pDC activation, induction of IFN-I, and CD95-mediated apoptosis.
第3组固有淋巴细胞(ILC3s)已被证明在促进抗菌免疫、维持上皮屏障功能和支持组织修复中发挥作用。ILC3改变与慢性炎症和炎症性疾病相关;然而,由于缺乏一个强大的模型,该细胞群在HIV-1感染中的特征和相关调节机制尚不清楚。在此,我们确定功能性人类ILC3s在人源化小鼠的淋巴器官中发育,并且在该模型中持续的HIV-1感染会耗尽ILC3s,正如在慢性HIV-1感染患者中观察到的那样。在HIV-1感染的小鼠中,有效的抗逆转录病毒疗法可逆转ILC3s的丧失。HIV-1依赖性的ILC3s减少需要浆细胞样树突状细胞(pDCs)、I型干扰素(IFN-I)和CD95/FasL途径,因为分别对这些进行靶向消耗或阻断可在体内和体外防止HIV-1诱导的ILC3s消耗。最后,我们确定HIV-1感染通过一种pDC和IFN-I依赖性机制诱导ILC3s上的CD95表达,该机制使ILC3s对CD95/FasL介导的凋亡敏感。我们得出结论,慢性HIV-1感染通过pDC激活、IFN-I诱导和CD95介导的凋亡来耗尽ILC3s。
J Clin Invest. 2015-9
J Clin Invest. 2017-10-30
J Leukoc Biol. 2010-2-9
Vaccines (Basel). 2025-1-28
Vaccines (Basel). 2024-9-4
Cell Mol Immunol. 2024-9
Front Immunol. 2023
Cancer Biol Med. 2023-10-9
PLoS Pathog. 2014-12-11
Cell Host Microbe. 2015-1-14
Blood. 2014-4-28